There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allakos (ALLK – Research Report) and Crinetics Pharmaceuticals (CRNX – Research Report) with bullish sentiments.
Allakos (ALLK)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Allakos today. The company’s shares closed last Monday at $2.88.
According to TipRanks.com, Slutsky is a 4-star analyst with an average return of
Allakos has an analyst consensus of Moderate Buy, with a price target consensus of $5.13, representing a 59.8% upside. In a report released yesterday, William Blair also upgraded the stock to Buy with a $3.00 price target.
See today’s best-performing stocks on TipRanks >>
Crinetics Pharmaceuticals (CRNX)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Crinetics Pharmaceuticals today and set a price target of $46.00. The company’s shares closed last Monday at $33.25, close to its 52-week high of $35.49.
According to TipRanks.com, Gershell is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Crinetics Pharmaceuticals with a $47.11 average price target, representing a 36.4% upside. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $56.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALLK:
